These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 39204130)
1. Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study. Guo Z; Ding Y; Wang M; Zhai Q; Liu J; Du Q Pharmaceuticals (Basel); 2024 Aug; 17(8):. PubMed ID: 39204130 [TBL] [Abstract][Full Text] [Related]
2. Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database. Liu W; Lin S; Zhu X; Yin L; Liu Q; Lei S; Feng B Front Immunol; 2024; 15():1433075. PubMed ID: 39290710 [TBL] [Abstract][Full Text] [Related]
3. Dermatologic Adverse Events Associated With Chimeric Antigen Receptor T-Cell Therapy: A Pharmacovigilance Analysis of the FDA Reporting System. Storgard R; Dusza S; Shouval R; Scordo M; Markova A Transplant Cell Ther; 2024 Oct; 30(10):1035.e1-1035.e7. PubMed ID: 38945480 [TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database. Ren X; Zhang G; Li G; Wang Y BMC Cancer; 2024 Jan; 24(1):10. PubMed ID: 38166723 [TBL] [Abstract][Full Text] [Related]
5. CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017-2023). Shi J; Liu X; Jiang Y; Gao M; Yu J; Zhang Y; Wu L Front Pharmacol; 2024; 15():1434231. PubMed ID: 39234101 [TBL] [Abstract][Full Text] [Related]
6. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database. Fusaroli M; Isgrò V; Cutroneo PM; Ferrajolo C; Cirillo V; Del Bufalo F; Raschi E; Poluzzi E; Trifirò G Drug Saf; 2022 Aug; 45(8):891-908. PubMed ID: 35829913 [TBL] [Abstract][Full Text] [Related]
7. Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System. Zhai Y; Yuan L; Fang S; Liu S; Ye X; Shi W; Cao Y; He J; Hu F; Xu F Expert Opin Drug Saf; 2024 Oct; ():1-9. PubMed ID: 39410883 [TBL] [Abstract][Full Text] [Related]
8. Next-Generation Chimeric Antigen Receptor T-cells. Yi D; Gergis M; Hsu J; Yang Y; Bi X; Aljurf M; Gergis U Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):117-121. PubMed ID: 36537905 [TBL] [Abstract][Full Text] [Related]
9. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States. Maziarz RT; Yang H; Liu Q; Wang T; Zhao J; Lim S; Lee S; Dalal A; Bollu V Leuk Lymphoma; 2022 Sep; 63(9):2052-2062. PubMed ID: 35422192 [TBL] [Abstract][Full Text] [Related]
10. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T Front Immunol; 2022; 13():991092. PubMed ID: 36119032 [TBL] [Abstract][Full Text] [Related]
11. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Jacobson CA; Munoz J; Sun F; Kanters S; Limbrick-Oldfield EH; Spooner C; Mignone K; Ayuk F; Sanderson R; Whitmore J; Wang Y; Xu H; Dickinson M Transplant Cell Ther; 2024 Jan; 30(1):77.e1-77.e15. PubMed ID: 37890589 [TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care. Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma. Ghanem B Invest New Drugs; 2023 Oct; 41(5):710-718. PubMed ID: 37572232 [TBL] [Abstract][Full Text] [Related]
14. Real-world adverse events associated with CAR T-cell therapy among adults age ≥ 65 years. Zettler ME; Feinberg BA; Phillips EG; Klink AJ; Mehta S; Gajra A J Geriatr Oncol; 2021 Mar; 12(2):239-242. PubMed ID: 32798213 [TBL] [Abstract][Full Text] [Related]
15. Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Gagelmann N; Bishop M; Ayuk F; Bethge W; Glass B; Sureda A; Pasquini MC; Kröger N Transplant Cell Ther; 2024 Jun; 30(6):584.e1-584.e13. PubMed ID: 38281590 [TBL] [Abstract][Full Text] [Related]
16. Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma. Wesson W; Dima D; Suleman N; Saif MSI; Tabak C; Logan E; Davis JA; McGann M; Furqan F; Mohan M; Rashid A; Abdallah AO; Ullah F; Shune L; Mushtaq MU; Raza S; McGuirk J; Hamadani M; Anwer F; Hashmi H; Ahmed N Transplant Cell Ther; 2024 Sep; 30(9):876-884. PubMed ID: 38871056 [TBL] [Abstract][Full Text] [Related]
17. Neurological adverse events following CAR T-cell therapy: a real-world analysis. Gajra A; Zettler ME; Phillips EG; Klink AJ; Jonathan K Kish ; Fortier S; Mehta S; Feinberg BA Immunotherapy; 2020 Oct; 12(14):1077-1082. PubMed ID: 32808566 [No Abstract] [Full Text] [Related]
18. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL Biol Blood Marrow Transplant; 2020 Sep; 26(9):1581-1588. PubMed ID: 32561336 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results. Oluwole OO; Ray MD; Davies N; Bradford R; Jones C; Patel AR; Locke FL J Med Econ; 2024; 27(1):230-239. PubMed ID: 38240256 [TBL] [Abstract][Full Text] [Related]